Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature.
Golimumab is a human IgG monoclonal antibody specific for human tumor necrosis factor alpha. Golimumab has been approved for use in rheumatological conditions; however, its use in inflammatory bowel disease is still being evaluated in clinical trials. We report a case of an exacerbation of ulcerative proctitis after starting on golimumab for ankylosing spondylitis.
1Internal Medicine Department, University of Toledo Medical Center, Toledo, OH 2Division of Gastroenterology, UP Digestive Health, War Memorial Hospital, Marie, MI.
Muhammad Z
MZ
Bawany
Ehsan
E
Rafiq
Raja
R
Thotakura
Roberta
R
Lay
Ann L
AL
Silverman
Ali
A
Nawras
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D011349:Proctitis / Q000139:chemically induced / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000068879:Adalimumab